Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR Positive HER2 Negative Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Study completedNCT06375707
What this trial is testing

First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Not applicableStudy completedNCT05173103
What this trial is testing

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
University of Milano Bicocca 254
Early research (Phase 1)WithdrawnNCT04316169
What this trial is testing

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Who this might be right for
Solid TumorAdvanced Breast Cancer
Medical College of Wisconsin
Testing effectiveness (Phase 2)Active Not RecruitingNCT05810870
What this trial is testing

PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
MedSIR 14
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Early research (Phase 1)Active Not RecruitingNCT06257264
What this trial is testing

Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Who this might be right for
Breast CancerSmall Cell Lung CancerOvarian Cancer+9 more
BeiGene 103
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Early research (Phase 1)UnknownNCT05337657
What this trial is testing

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Genor Biopharma Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Testing effectiveness (Phase 2)Ended earlyNCT04862143
What this trial is testing

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 2
Testing effectiveness (Phase 2)Study completedNCT02732119
What this trial is testing

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 104
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Testing effectiveness (Phase 2)Ended earlyNCT04227327
What this trial is testing

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Who this might be right for
Advanced Breast Cancer
University of Milano Bicocca 31
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Next Page